COVID-19 Vaccines Currently under Preclinical and Clinical Studies, and Associated Antiviral Immune Response

• Published in: Vaccines (Basel) 2020-11, Vol.8 (4), p.649
• Main Authors: Jain, Swati, Batra, Himanshu, Yadav, Poonam, Chand, Subhash
• Format: Article
• Language: English
• Subjects: COVID-19; neutralizing antibodies; Review; SARS-CoV-2; vaccine development; vaccine platforms; vaccine response
• ISSN: 2076-393X; 2076-393X
• DOI: 10.3390/vaccines8040649

With a death toll of over one million worldwide, the COVID-19 pandemic caused by SARS-CoV-2 has become the most devastating humanitarian catastrophe in recent decades. The fear of acquiring infection and spreading to vulnerable people has severely impacted society's socio-economic status. To put an end to this growing number of infections and deaths as well as to switch from restricted to everyday living, an effective vaccine is desperately needed. As a result, enormous efforts have been made globally to develop numerous vaccine candidates in a matter of months. Currently, over 30 vaccine candidates are under assessment in clinical trials, with several undergoing preclinical studies. Here, we reviewed the major vaccine candidates based on the specific vaccine platform utilized to develop them. We also discussed the immune responses generated by these candidates in humans and preclinical models to determine vaccine safety, immunogenicity, and efficacy. Finally, immune responses induced in recovered COVID-19 patients and their possible vaccine development implications were also briefly reviewed.